Quell Therapeutics Signed an Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies
Shots:
- Quell will receive $85M up front incl. predominant cash & an equity investment, ~$2B upon achievement of milestones along with royalties. Quell will lead the process development & manufacturing at the end of the first-in-human study
- Quell retains an option to co-develop Treg cell therapies from the T1D program with AstraZeneca in the US. This option can be exercised after IND approval or at the end of the P-I/II study while AstraZeneca gets an option for further develop & commercialize candidates
- Quell retains full ownership of QEL-001 to prevent organ rejection, eliminating the need for immunosuppression in liver transplant patients. The collaboration focuses to develop autologous multi-modular Treg cell therapy for T1D & IBD using Quell’s toolbox of Treg cell engineering modules
Ref: Globenewswire | Image: Merck
Related News:- Merck and AstraZeneca's Lynparza (Olaparib) Receive NICE Recommendation for Maintenance Treatment of BRCA-Mutated Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
